Citicoline

DB12153ApprovedInvestigationalWithdrawnSmall molecule

Citicoline is an endogenous intermediate in the formation of phosphatidylcholine from choline which is thought to have neuroprotective effects. Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides.

Formula / weight: C₁₄H₂₆N₄O₁₁P₂ · 488.324 g/mol (avg)
Also known as: CDP-choline

Resolves to

Compound

UNII536BQ2JVC7CAS987-78-0ChEMBLCHEMBL1231700ChEBI16436KEGGD00057

Clinical / RWD

RxNorm997602ATCN06BX06

Structure

InChIKeyRZZPDXZPRHQOCG-OJAKKHQRSA-NSMILESC[N+](C)(C)CCOP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O

Targets

A0A0H2UQB5licC

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

36Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

4ContraindicationsEach with its own population and attribute set

141Marketed productsAcross 6 countries and 57 labellers

1ATC codeIncluding every combination product, plus 16 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Citicoline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account